B-Myb is a highly conserved member of the Myb family of transcription factors, which has been implicated in cell cycle regulation. B-Myb is expressed in most proliferating cells and its activity is highly regulated around the G1/Sphase border of the cell cycle. It is generally assumed that B-Myb regulates the expression of genes that are crucial for cell proliferation; however, the identity of these genes, the molecular mechanisms by which B-Myb stimulates their expression and the involvement of other proteins have not been sufficiently clarified. We have employed the hamster cell line ts13 as a tool to demonstrate a functional link between B-Myb and the coactivator TAF II 250, a key component of the transcriptional machinery which itself is essential for cell proliferation. ts13 cells express a pointmutated version of TAF II 250 whose intrinsic histone acetyl transferase activity is temperature sensitive. Transactivation of Myb-responsive reporter genes by BMyb is temperature-dependent in ts13 cells but not in ts13 cells, which have been rescued by transfection with an expression vector for wild-type TAF II 250. Furthermore, B-Myb and TAF II 250 can be coprecipitated, suggesting that both proteins are present in a complex. The formation of this complex is dependent on the DNA-binding domain of B-Myb and not on its transactivation domain. Taken together, these observations provide the first evidence that the coactivator TAF II 250 is involved in the activation of Myb responsive promoters by B-Myb. The finding that BMyb transactivation is dependent on a key coactivator involved in cell cycle control is consistent with and strengthens the idea that B-Myb plays a crucial role as a transcription factor in proliferating cells.
Introduction
The initiation of transcription by RNA polymerase II is a highly regulated process in which the cooperation of DNA-binding transcription factors with the basal transcriptional machinery and the modulation of chromatin structure play crucial roles. A central component of this machinery is the transcription factor IID (TFIID), which is composed of the TATA boxbinding protein (TBP) and a number of TATA boxbinding protein-associated factors (TAFs). The largest subunit of the TFIID complex, TAF II 250, plays a key role in this complex by acting as a scaffold for the assembly of other TAFs and TBP into TFIID and by displaying various enzymatic activities that facilitate transcriptional initiation (Albright and Tjian, 2000; Wassarman and Sauer, 2001) . TAF II 250 possesses acetyltransferase activity, which is located in the central domain of the protein and is able to acetylate histones as well as other components of the basal transcriptional machinery (Mizzen et al., 1996; Imhof et al., 1997) . In addition, TAF II 250 contains two independent serine/ threonine-specific protein kinase domains located at the N-and C-terminus (Dikstein et al., 1996; O'Brien and Tjian, 1998) . Finally, TAF II 250 has ubiquitin-activating/conjugating activity and ubiquitinates histone H1 (Pham and Sauer, 2000) .
TAF II 250 is an essential protein which is required for progression through the cell cycle. The ts13 hamster cell line harbors a single point mutation in the gene encoding TAF II 250, which renders the acetyltransferase activity of TAF II 250 temperature-sensitive (Hisatake et al., 1993; Dunphy et al., 2000) . When ts13 cells are grown at the nonpermissive temperature, they arrest in the G1 phase of the cell cycle and undergo apoptosis. A large number of genes have been identified whose expression is affected at the restrictive temperature (O'Brien and Tjian, 2000) , including the genes for cyclins A and D1 (Wang and Tjian, 1994; SuzukiYagawa et al., 1997; Wang et al., 1997) . A number of studies have shown that, depending on the gene, TAF II 250 acts on its targets by affecting basal promoter activity or by mediating the effects of upstream activators or by doing both. For example, the TAF II 250 dependence of cyclin A expression is mediated by the basal promoter as well as by an upstream sequence element of the cyclin A gene (Wang et al., 1997) . These two effects appear to be independent, as upstream binding sites for activators can confer TAF II 250 dependence on promoters that are normally TAF II 250 independent (Wang et al., 1997) . A number of reports have shown that TAF II 250 interacts with and is regulated by several activators, such as the HIV Tat (Weissman et al., 1998) , adenovirus E1A (Siegert et al., 2000) , c-Jun (Lively et al., 2001 ) and other transcriptional regulators, including the retinoblastoma (Siegert and Robbins, 1999) and MDM2 proteins (Levaillard and Wasylyk, 1997) . The identification and analysis of genes and of transcriptional activators whose activity depends on TAF II 250 will undoubtedly provide further insight into the role of TAF II 250 during the cell cycle.
The transcription factor B-Myb is a highly conserved member of the myb proto-oncogene family, which consists of A-Myb, B-Myb and c-Myb (Nomura et al., 1988; Bouwmeester et al., 1992; Foos et al., 1992; Lam et al., 1992) , B-Myb is expressed in a wide variety of dividing cells and a large body of evidence suggests that B-Myb plays a crucial role during cell proliferation. Bmyb expression is downregulated in quiescent fibroblasts and subsequent re-entry into the cell cycle induces expression of B-myb in the late G1/early S phase (Lam et al., 1992; Lam and Watson, 1993) . The cell cycle regulated B-myb expression is dependent on an E2F-binding site within the B-myb promoter and involves negative regulation by E2F complexes (Lam and Watson, 1993; Zwicker et al., 1996) . During mouse embryogenesis, B-myb expression is tightly linked to the proliferative activity of cells and tissues (Sitzmann et al., 1996) . B-myb antisense oligonucleotides inhibit cell proliferation (Arsura et al., 1992) , while overexpression of B-myb enables cells to escape the cell cycle arrest that is induced by overexpression of the tumor suppressor protein p53 and mediated by the Waf1/Cip1 protein (Lin et al., 1994) . In addition to the control of B-myb mRNA expression, the activity of the B-Myb protein is regulated by post-translational modification. Phosphorylation of B-Myb by cyclin A/Cdk2 in the early S phase of the cell cycle relieves repression mediated by an inhibitory domain located at the carboxyl-terminus and thereby stimulates the transactivation potential of B-Myb (Robinson et al., 1996; Lane et al., 1997; Sala et al., 1997; Saville and Watson, 1998; Bartsch et al., 1999) . In addition to stimulating B-Myb activity, cyclin A/Cdk2-mediated phosphorylation triggers polyubiqitination of B-Myb and directs its degradation by the 26S proteasome (Charrasse et al., 2000) . Recently, we showed that cyclin D1, in contrast to cyclin A, inhibits the activity of B-Myb in a Cdk-independent manner by physically interacting with B-Myb (Horstmann et al., 2000a) . Finally, the coactivator p300/CBP interacts with B-Myb and increases its transcriptional activity (Bessa et al., 2001; Johnson et al., 2002) .
The long-standing observation that B-Myb, like TAF II 250, plays a crucial role in proliferating cells has prompted us to look for a functional link between both proteins. The work presented here directly supports the idea of such a link by demonstrating that transactivation mediated by B-Myb is dependent on TAF II 250 and that both proteins are present in a complex in vivo.
Results

Transactivation mediated by B-Myb depends on functional TAF II 250
TAF II 250 has been shown to control the expression of genes that are required during cell proliferation. Since B-Myb is a transcription factor that plays a crucial role in proliferating cells, we were interested in the possibility that there is a functional link between B-Myb and TAF II 250. To address this possibility, we investigated whether activation at the Myb responsible reporter gene pGL3-3xATk-Luc by full-length B-Myb or by the C-terminal deletion mutant B-Myb-D3 is temperaturedependent in the ts13 hamster cell line, which carries a temperature-sensitive allele of the TAF II 250 gene (Figure 1a ). This reporter gene contains three copies of a Myb-binding site from the chicken mim-1 gene and is commonly used to study transactivation mediated by Myb proteins. This experiment demonstrated that transactivation of the reporter gene by B-Myb and B-Myb-D3 was indeed temperature-sensitive in ts13 cells. This was particularly evident when the Cterminally truncated form of B-Myb was used. As shown before , this form of B-Myb is more active than full-length B-Myb because an inhibitory domain, located at the C-terminus of BMyb, has been deleted in this mutant. The poor activity of the reporter gene at the nonpermissive temperature was not because of insufficient amounts of B-Myb protein; as demonstrated by the Western blot shown in Figure 1c , there was actually an increase in the amount of B-Myb and B-Myb-D3 at the nonpermissive temperature, suggesting that the degree of inhibition of B-Myb activity at the restrictive temperature is even higher than is evident from the data shown in Figure 1a . We concluded from this experiment that TAF II 250 is required for efficient transactivation by full-length or truncated B-Myb. To substantiate this conclusion, we performed the same experiment using ts13 cells which had been stably transfected with an expression vector for wild-type (wt) TAF II 250 (referred to as ts13HAX250) and which do not show a temperaturesensitive cell-cycle phenotype. As shown in Figure 1a , B-Myb-mediated transactivation was no longer temperature-dependent in these cells, confirming that the decrease in the transactivation potential of B-Myb and B-Myb-D3 observed in ts13 cells upon temperature shift is indeed because of the lack of TAF II 250. To corroborate these findings, we also used a reporter gene (pGL3-A(-144)wt-Luc) containing the Myb-responsive promoter of the tom-1 gene (Burk et al., 1997) for a transactivation experiment (Figure 1b) . The tom-1 promoter was activated less efficiently by B-Myb-D3 than the tk promoter construct; however, it is obvious that the activation of the tom-1 promoter was also temperature-dependent when ts13 cells but not when tsHAX250 cells were used (Figure 1c) . The finding that the activity of the truncated form of B-Myb is impaired at the nonpermissive temperature in ts13 cells is particularly interesting because it suggests that the effect of TAF II 250 on B-Myb is unlikely an indirect effect mediated by cyclin A, which is a transcriptional target of TAF II 250 (Wang and Tjian, 1994; Wang et al., 1997) . The activity of B-Myb-D3 is independent of cyclin A , hence the decrease in activity of truncated B-Myb at nonpermissive temperature cannot be explained by the lack of cyclin A under these conditions. Taken together, these results provide the first evidence that B-Myb requires TAF II 250 for transactivation of B-Myb-responsive promoters.
B-Myb does not abrogate the TAF II 250 deficiency in ts13 cells
The experiments shown in Figure 1 suggest a functional link between B-Myb-dependent transactivation and TAF II 250. To further explore this link, we were interested to determine whether overexpression of BMyb is able to overcome the TAF II 250 deficiency in ts13 cells. To address this issue, we transfected an expression vector for B-Myb or B-Myb-D3 into ts13 cells and cultivated them at the nonpermissive temperature. As controls, we transfected the cells with an expression vector for wt TAF II 250 or with empty expression vector. As expected, wild-type TAF II 250 was able to complement the ts13 mutant giving rise to colonies of transfected cells that grew at 391C. By contrast, none of the B-Myb constructs was able to rescue the mutant cells at nonpermissive temperature (Figure 2 ), clearly showing that B-Myb does not complement the TAF II 250 deficiency in ts13 cells.
Coimmunoprecipitation of TAF II 250 and B-Myb
The experiments illustrated in Figure 1 show that transactivation by B-Myb depends on TAF II 250, but they do not reveal the nature of this dependence. One obvious possibility is that the activation of a promoter by B-Myb requires TAF II 250 to be present at that promoter. In this case, we might expect to find B-Myb and TAF II 250 in a complex in vivo. To investigate whether this is the case, we performed coimmunoprecipitation experiments using extracts from cells expressing B-Myb, TAF II 250 or both. As illustrated in Figure 3 immunoprecipitation with antibodies specific for B-Myb or the HA-tag. Finally, the immunoprecipitates were fractionated by SDS-polyacrylamide gel electrophoresis (PAGE) and analysed by autoradiography. As shown in Figure 3 , the transfected full-length TAF II 250 could be efficiently coprecipitated with B-Myb-specific antiserum, suggesting that TAF II 250 is present in a complex with B-Myb. Control immunoprecipitations of cells transfected with B-Myb or TAF II 250 expression vectors alone showed that TAF II 250 could only be precipitated with B-Myb-specific antiserum when B-Myb was present. This confirms that the observed coprecipitation was specific and was not caused by crossreactivity of the antisera or insufficient washing of the immunoprecipitates. Surprisingly, the anti-HA antibody did not coprecipitate B-Myb, although under the same conditions antibodies against B-Myb coprecipitated TAF II 250. We do not know the reason why coprecipitation of both protein works only in one direction. Comparison of the relative intensities of the protein bands corresponding to B-Myb and TAF II 250 suggests that B-Myb is in excess over TAF II 250. It is therefore possible that the amount of coprecipitated B-Myb is below the limit of detection. Alternatively, it is also possible that the HA-epitope is not accessible to the antibody in the complex.
In the same experiment we also coexpressed B-Myb with different deletion mutants of TAF II 250 to identify the domain of TAF II 250, which is responsible for coprecipitation with B-Myb. As seen in Figure 3 coprecipiation was most effective when the middle region of TAF II 250 was present (constructs D400 and DNC). The C-terminal domain (D1225) was not coprecipitated, whereas a protein that corresponds to the amino-terminus of TAF II 250 (DXba) was coprecipitated weakly (Figure 3 ). Taken together, it appears that two nonoverlapping regions of TAF II 250 independently mediate coprecipitation with B-Myb. One of these regions is located in the central part of TAF II 250 and mediates efficient coprecipitation with B-Myb, while the other is located in the amino-terminal domain of the protein and coprecipitates with B-Myb considerably weaker.
TAF II 250 has weak histone acetyltransferase (HAT) activity which has been mapped to the center of the protein. The HAT activity of TAF II 250 is temperature sensitive in ts13 cells (Dunphy et al., 2000) , suggesting that the acetylation of histones and possibly of other target proteins by TAF II 250 plays a role in TAF II 250-dependent gene expression (Dunphy et al., 2000) . The results presented so far raised the question of whether BMyb is acetylated by TAF II 250. However, we could not detect any acetylation of B-Myb in the presence TAF II 250 using antibodies specific for acetylated lysine (data not shown). Thus, there is no evidence that B-Myb is a substrate for the HAT activity of TAF II 250.
Coprecipitation of TAF II 250 and B-Myb depends on the DNA-binding domain of B-Myb
To map the domain of B-Myb, which is involved in complex formation with TAF II 250, we expressed fulllength TAF II 250 with different deletion mutants of B-Myb, followed by labeling of the cells with [ Figure 4) . B-Myb-Ex9A-is a natural splice variant of B-Myb lacking the so-called exon 9A (Kamano et al., 1995) . This protein is inactive as a transcriptional activator because it lacks a functional transactivation domain (Horstmann et al., 2000b) . B-Myb-Ex9A-was also able to coprecipitate TAF II 250, demonstrating that the ability to form a complex with TAF II 250 does not depend on the transactivation domain of B-Myb.
To show that the B-Myb DNA-binding domain not only mediates the formation of a complex between BMyb and TAF II 250 but is also crucial for the functional cooperation of both proteins, we fused the major transactivation domain of B-Myb (Horstmann et al., 2000b) either to the Gal4 DNA-binding domain or to To substantiate our results and provide additional evidence that B-Myb and TAF II 250 are present in a complex also in untransfected cells, we performed coimmunoprecipitation experiments with Hela cells, which express both B-Myb and TAF II 250 endogenously. Extracts from these cells were first immunoprecipitated with B-Myb-specific antibodies or with an anti-His-tag antibody as an irrelevant control. The immunoprecipitates were then fractionated by SDS-PAGE and analysed by Western blotting using TAF II 250-specific antibodies. Figure 6 shows that a small fraction of the endogeous TAF II 250 was indeed coprecipitated with the B-Myb antiserum but not with the control antiserum. Thus, this experiment shows that B-Myb and a small fraction of the TAF II 250 are present in a 
Discussion
B-Myb is a highly conserved vertebrate member of the Myb transcription factor family, is expressed in virtually all proliferating cell types. B-myb mRNA expression peaks around the G1-/S-phase transition of the cell cycle. In addition, the activity of the B-Myb protein is regulated by cyclin A/Cdk2-dependent phosphorylation as well as by direct interaction with cyclin D1 (Lam et al., 1992; Robinson et al., 1996; Saville and Watson, 1998; Horstmann et al., 2000a) . Since B-Myb expression and function are strictly correlated with cell proliferation and highly regulated during the cell cycle, it is generally assumed that B-Myb plays an important role as a transcriptional regulator in proliferating cells. B-Myb has been shown to interact with p300/CBP and poly(ADP-ribose) polymerase (PARP), both of which stimulate the transactivation potential of B-Myb, as well as with the nuclear corepressors N-CoR and SMRT, which downmodulate B-Myb activity (Cervellera and Sala, 2000; Bessa et al., 2001; Johnson et al., 2002; Li and McDonnell, 2002) . The physiological relevance of the interaction of B-Myb with these proteins is not yet fully understood. It is also not known whether these are the only coactivators or corepressors recruited by B-Myb.
Here, we have employed the hamster cell line ts13 as a tool to demonstrate a functional link between B-Myb and the coactivator TAF II 250, a key component of the transcriptional machinery, which is itself essential for cell proliferation. The evidence for this link is based on two major observations. Firstly, we have shown that transactivation mediated by B-Myb is temperaturesensitive in the ts13 hamster cell line. ts13 cells carry a point mutation in the endogenous TAF II 250 gene resulting in a protein whose HAT activity is temperature-sensitive. By contrast, ts13 cells which have been rescued by overexpression of wt TAF II 250 no longer show temperature-dependent activity of B-Myb. These results provide strong evidence that B-Myb-mediated transactivation is dependent on the HAT activity of TAF II 250. Secondly, we have shown that B-Myb and TAF II 250 can be coprecipitated from cells transfected with expression vectors for both proteins as well as from cells expressing these proteins endogenously. The amount of endogenous TAF II 250 which could be coprecipitated with B-Myb was very low, which is not surprising, given the fact that TAF II 250 is involved in the transcription of numerous genes (O'Brien and Tjian, 2000) . TAF II 250 therefore probably is involved in complex formation with other transcription factors besides B-Myb. It is also possible that coprecipitation of B-Myb and TAF II 250 is less efficient in the endogenous situation than in the transfection experiment, because most of the endogenous TAF II 250 will be embedded in large complexes with other proteins. By contrast, because of overexpression there is likely a large pool of free TAF II 250 in the transfected cells. The presence of other proteins in the B-Myb/TAF II 250 complex in the endogenous situation might hinder the binding of the antibodies used for coprecipitation. We do not know whether B-Myb and TAF II 250 are direct interaction partners; although our in vivo studies provide evidence for interaction, binding could be mediated by another proteins. In vitro protein-binding experiments using bacterially expressed B-Myb and in vitro translated TAF II 250 failed to show specific binding of B-Myb to TAF II 250 (data not shown), suggesting that the interaction might indeed be indirect, as in the case of the transcription factor Sp1, whose interaction with TAF II 250 is mediated by TAF II 110, another component of TFIID (Gill et al., 1994) . However, the lack of binding of B-Myb and TAF II 250 in vitro might also be because of the limitations inherent in this type of assay. For example, it is possible that the in vitro expressed proteins do not fold properly and therefore are not able to bind to each other. Irrespectively of whether the interaction of B-Myb and TAF II 250 is direct or indirect, our results provide the first evidence for a functional link between these two proteins. Since TAF II 250 is essential for cell proliferation, these results are consistent with and strengthen the idea that B-Myb plays a key role as a transcription factor in proliferating cells. Furthermore, our observations suggest that at least some of the genes whose expression is affected in ts13 cells will be targets for B-Myb. The cyclin D1 gene is a candidate for this group of genes as it is downregulated in ts13 cells at non-permissive temperature (SuzukiYagawa et al., 1997; Wang et al., 1997) and has been postulated to be activated by B-Myb (Sala and Calabretta, 1992) .
We have shown that it is the DNA-binding domain of B-Myb that is required for the interaction with TAF II 250. The amino-terminal part of B-Myb which contains the DNA-binding domain is not only necessary but appears also to be sufficient for the formation of a and Sala, 2000) , suggesting that PARP acts as a coactivator when bound to B-Myb. Thus, the DNA-binding domain of B-Myb is not only required for protein-DNA interaction but also stimulates transcription via specific protein-protein interactions involving at leat two coactivators. That the Myb DNA-binding domain is involved in protein-protein interactions has also been shown in case of v-Myb and cMyb (Mink et al., 1996; Tahirov et al, 2002) , whose interaction with members of the C/EBP transcription factor family is mediated by their DNA-binding domain. Previous work has shown that B-Myb directly interacts with the coactivator p300/CBP via the central part of B-Myb, which contains the transactivation domain (Horstmann et al., 2000b) . B-Myb, therefore, appears to communicate with the transcriptional machinery by at least two routes involving different coactivators and two distinct domains of the protein (the DNA-binding and the transactivation domain). A complex strategy for gene activation like this might increase the regulatory flexibility of the system and provide a means for increasing the specificity of B-Myb for particular target genes. The observation that B-Myb-dependent transactivation is decreased at the restrictive temperature in ts13 cells suggests that the HAT domain of TAF II 250 and presumably its enzymatic activity is required for B-Myb activity. At present, it is not clear what the exact role of the HAT activity is, that is, which protein(s) must be acetylated by TAF II 250 as a prerequisite for B-Mybdependent stimulation of the tk promoter. The HAT activity of TAF II 250 apparently is not required for the basal promoter function because the tk promoter by itself is not temperature-dependent in ts13 cells. Temperature-dependent activity is only seen in the presence of Myb-binding sites and B-Myb protein. Therefore, the HAT activity of TAF II 250 is likely required for the communication of B-Myb with the transcriptional machinery that assembles at the basal tk promoter. Since B-Myb itself apparently is not acetylated by TAF II 250 at detectable levels, it might be speculated that TAF II 250 acetylates (an) additional, as yet unknown protein(s) involved in B-Myb-dependent transactivation. However, at present we cannot dismiss the alternative possibility that B-Myb just interacts with the HAT domain of TAF II 250 and that the interaction itself is temperature-sensitive because of conformational changes.
The scenario described here for B-Myb is somewhat reminiscent of the role of TAF II 250 at the cyclin A promoter. In that case, it was shown that one function of the HAT activity of TAF II 250 was to mediate the stimulatory effect of an upstream element on the activity of the basal cyclin A promoter (Wang et al., 1997) . It was also found that the upstream element, which contains ATF binding sites, could confer TAF II 250-dependence on a heterologous, TAF II 250-independent promoter. Thus, the results presented here provide another example in which upstream binding sites (Myb sites in this case) in the presence of a cognate transcription factor (B-Myb) confer TAF II 250 dependence on a basal promoter. Further analysis of the molecular details of the interplay of B-Myb and TAF II 250 will probably shed light on the mechanisms by which B-Myb regulates the expression of cellular genes and the role of the HAT activity of TAF II 250.
Materials and methods
Cell culture
The ts13 cell line and its derivative ts13HAX250 have been described (Talavera and Basilico, 1977; Wang et al., 1997) . The cells were grown at 33.51C (permissive temperature) or at 39.51C (nonpermissive temperature) in DMEM supplemented with 10% fetal calf serum. The quail fibroblast cell line QT6 (Moscovici et al., 1977) was grown in Iscove's modified DMEM supplemented with 8% fetal calf serum and 2% chicken serum. Trichostatin A (TSA) was added to some cultures at a concentration of 100 ng/ml.
Eukcaryotic expression vectors
Expression vectors for full-length mouse B-Myb (pMuBMEx9A+) and for deletion mutants B-Myb D3 (pMuBMEx9-a+D3) and B-Myb DFsp (pMuBMDFsp) have been described before (Kamano and Klempnauer, 1997 ). An expression vector for the Gal4/B-Myb fusion protein Gal4/B-Myb-D2 was described elsewhere (Horstmann et al., 2000b) . pB-Myb-D2 encodes a fusion protein of the B-Myb DNA-binding and the major transactivation domain of B-Myb and was constructed as follows: B-Myb sequences encoding the DNA-binding domain (amino acids 1-190 of mouse B-Myb) were PCRamplified using the primers MuBM143fd GCGGATC-CATGTCTCGGCGGACGCGC and MuBM712bd GCGAA TTCTGGGAAACCTCCCGTGTCGAC. The sequences encoding domain D2 of B-Myb were generated similarly using the primers MuBM859fd GCATGAATTCCGAGGAGGA-GATTGCCATAG and MuBM1271bd GCATTCTAGAC-TAAAGGCGGTACTCAGTCACA. The DNA fragments were digested with HindIII and EcoRI or EcoRI and XbaI, respectively, and cloned between the HindIII and XbaI sites of pCDNA3 (Invitrogen). The resulting plasmid encodes a protein consisting of amino acids 1-190 and 240-376 of mouse B-Myb. The TAF II 250 expression vector pCS2+ HA-WTTAF250 (encoding HA-tagged full-length human TAF II 250) was obtained from EH Wang. Expression vectors for HA-tagged deletion mutants of TAF II 250 were generated as follows. First, a CMV-based expression vector for HAtagged full-length TAFII250 was constructed by cloning a double-stranded oligonucleotide encoding the HA-tag and the complete coding region of TAFII250 (obtained as a NdeI/SpeI fragment from pCS2+HA-WTTAF250) between the HindIII and XbaI sites of pCDNA3 (Invitrogen). The HA-tag oligonucleotide was obtained by annealing the single strands AGCTTGGATCCACCATGGGCTACCCCTACGACGTGC CCCGACTACGCCATCGAAGGCCGCCA and TATGGC GGCCTTCGATGGCGTAGTCGGGCACGTCGTAGGGG TAGCCCATGGTGGATCCA. The resulting plasmid, pHAh-TAF250, was used to construct expression vectors encoding various deletions of TAFII250. pHAhTAF250-DBgl, encoding a HA-tagged protein which consists of amino acids 1-1419 of TAFII250, was obtained by cloning a 4.3 kb BamHI/BgIII fragment from pHAhTAF250 into the BamHI site of pCDNA3. pHAhTAF250-DXba (HA-tagged amino acids 1-401 of TAFII250) was generated by the HA-tag oligonucleotide and a NdeI/XbaI fragment from pCS2+HA-WTTAF250 (encoding the first 401 amino acids of TAFII250) between the HindIII and XbaI sites of pCDNA3. To generate N-terminal deletion mutants, the full-length TAFII250 coding region (including the HA-tag) was subcloned as a HindIII/SpeI fragment between the HindIII and XbaI sites of pbluescript. The resulting plasmid (pblueHAhTAF250) was then digested with NdeI and XbaI, followed by fill-in of the restriction sites and religation to generate pblueHAhTAF250-D400 (lacking the first 400 amino acids of TAFII250) or with NdeI and EcoRI, followed by fill-in of the restriction sites and religation to obtain pblueHAhTAF250-D1225 (lacking the first 1225 amino acids of TAFII250). The insert fragments of these plasmids were then subcloned as BamHI/NotI fragments between the BamHI and NotI sites of pCDNA3 to obtain pHAhTAF250-D400 and pHAhTAF250-D1225. In addition, a BamHI/BglII fragment of pblueHAhTAF250-D400 was cloned into the BamHI site of pCDNA3 to obtain pHAhTAF250-DNC. These plasmids encode deleted forms of TAFII250 containing amino acids 401-1893 (pblueHAhTAF250-D400), amino acids 1226-1893 (pHAhTAF250-D1225) and amino acids 401-1420 (pHAhTAF250-DNC). All deletion mutants of TAFII250 carry an N-terminal HA-tag.
Reporter genes, transfections, luciferase and b-galactosidase assays
The Myb-inducible reporter plasmids pGL3-3xATk-Luc and pG5-tk-Luc have been described (Horstmann et al., 2000b; Yang et al., 2001) . pCMVb was obtained from Clontech. Cells were transfected as described (Burk et al., 1993) and harvested 24 h after transfection. Preparation of cell extracts, luciferase and b-galactosidase assays were performed as described (Burk et al., 1993) .
In vivo coimmunoprecipitation
To detect complexes of B-Myb and TAF II 250 in vivo, QT6 cells were transfected with the appropriate expression vectors. After 24 h, the cells were radiolabeled for 6 h with 100 mCi of [ 35 S]methionine ml (specific activity, >800 Ci/mmol), washed with PBS, and lysed in ice-cold ELB lysis buffer (50 mm TrisHCl, PH 7.5; 120 mm NaCl; 1 mm EDTA; 6 mm EGTA; 20 mm NaF; 15 mm sodium pyrophoshate; 1 mm PMSF; 0.1 % (v/v) NP-40). All subsequent steps were carried out on ice. After shearing the DNA with a syringe, insoluble material was removed by centrifugation for 30 min at 41C and 14 000 r.p.m. The supernatant was divided into two aliquots, and antibodies against mouse B-Myb (N19, St Cruz) or the HA-tag (HA.11, BabCO) were added. After incubation overnight at 41C, protein A sepharose was added, incubated for 1 h and washed three times with lysis buffer and once with PBS. Finally, the immunoprecipitated proteins were analysed by SDS-PAGE and autoradiography.
To detect complexes of endogenous B-Myb and TAF II 250, Hela cells were lysed in ELB lysis buffer. Aliquots of the cell extract were incubated at 41C with antibodies against the Nterminus of B-Myb (N19; St Cruz) or against the His-tag (H-15; St Cruz). Immunoprecipitates were collected by incubation with protein A sepharose, followed by three washes with ELB buffer. The immunoprecipitates were then analysed by SDS-PAGE and Western blotting using antibodies against B-Myb (N19; St Cruz) or TAFII250 (6B3; St Cruz).
Western blotting
Immunostaining of mouse B-Myb proteins transferred to nitrocellulose was performed as described (Kamano et al., 1995) . B-Myb proteins were detected with a rabbit antiserum raised against the amino-terminus of B-Myb (N19, St Cruz). TAF II 250 was detected with the HA-specific monoclonal antibody HA.11 (BabCO) or with the TAFII250-specific antibody 6B3 (St Cruz). Acetylated B-Myb was detected with antibodies against acetyl-lysine (Ac-K-103, Cell Signaling Technology).
